24 stories mentioning IONSUpdated 9d ago
Every FINWIRES story that references IONS, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Ionis Pharmaceuticals (IONS) has an average rating of overweight and mean price target of $105.45, according to analysts polled by FactSet.Price: $75.25, Change: $+0.42, Percent Change: +0.55%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Ionis delivered robust Q1 2026 results with total revenue surging to $246M (+87% Y/Y), fueled by strong commercial execution and approximately $95M in R&D milestone payments. Product sales reached $43M compared to just $6M in the prior year period, with TRYNGOLZA generating $27M (+350% Y/Y) and DAWNZERA contributing $16M (+125% sequential growth). The accelerating momentum across its independent launch portfolio demonstrates strong commercial execution, in our view. Management raised 2026 revenue guidance substantially to $875M-$900M (from $800M-$825M) and improved operating loss guidance to $425M-$475M (from $500M-$550M). The company also increased olezarsen peak sales guidance to over $3B from over $2B, reflecting growing confidence in the severe hypertriglyceridemia market opportunity. With multiple regulatory catalysts ahead, including potential approvals for olezarsen and zilganersen, we believe Ionis appears well-positioned for continued growth.
Ionis Pharmaceuticals (IONS) said a study shows its zilganersen 50 mg demonstrated statistically significant results in patients aged five and older living with Alexander disease, a rare and often fatal neurodegenerative disorder.The pivotal study met its primary endpoint with the drug showing clinically meaningful stabilization of gait speed as assessed by the 10-meter walk test in patients, the company said Tuesday in a statement.New data from the Gross Motor Function Measure-88 showed that younger children aged two to four who received zilganersen improved more in gross motor function than those in the study's control group, the company said.Zilganersen demonstrated a favorable safety and tolerability profile, with most adverse events mild or moderate in severity, Ionis said.The drug is under priority review at the US Food and Drug Administration, which is expected to make an approval decision by Sept. 22, Ionis said.Price: $75.13, Change: $+0.25, Percent Change: +0.34%
Ionis Pharmaceuticals (IONS) has an average rating of overweight and mean price target of $103.75, according to analysts polled by FactSet.
Showing 21-24 of 24
